Design, Synthesis, and Structure–Activity Relationship of <i>N</i>-Aryl-<i>N</i>′-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy
作者:Zhipeng Chen、Lina Zhang、Junjie Yang、Lu Zheng、Fanjie Hu、Siqin Duan、Kutty Selva Nandakumar、Shuwen Liu、Hang Yin、Kui Cheng
DOI:10.1021/acs.jmedchem.0c02266
日期:2021.6.10
cells. To the best of our knowledge, it is the first species-specific TLR1/2 agonist reported until now. Moreover, SMU-C80 increased the percentage of T, B, and NK cells ex vivo and activated the immune cells, which suppressed cancer cell growth in vitro. In summary, we obtained a highly efficient and specific human TLR1/2 agonist that acts through the MyD88 and NF-κB pathway, facilitating cytokine release
之前对 1000 万种化合物的虚拟筛选产生了两种新的非脂肽样化学型作为 TLR2 激动剂。在此,我们介绍了我们最初命中的 1-苯基-3-(噻吩-2-基) 脲的化学优化,这导致将 SMU-C80 (EC 50 = 31.02 ± 1.01 nM)鉴定为 TLR2 特异性生物活性提高 370 倍的激动剂。机理研究表明,SMU-C80 通过 TLR1/2 募集接头蛋白 MyD88 并触发 NF-κB 通路以从人类而非鼠类细胞中释放细胞因子,例如 TNF-α 和 IL-1β。据我们所知,它是迄今为止报道的第一个物种特异性 TLR1/2 激动剂。此外,SMU-C80 增加了离体T、B 和 NK 细胞的百分比并激活免疫细胞,从而抑制体外癌细胞的生长。总之,我们获得了一种高效且特异的人 TLR1/2 激动剂,它通过 MyD88 和 NF-κB 途径起作用,促进细胞因子的释放和免疫细胞的同时激活,进而影响癌细胞的凋亡。